Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Nuvalent reveals preclinical data on cancer drug zidesamtinib
CAMBRIDGE, Mass. - Nuvalent, Inc., a clinical-stage biopharmaceutical company valued at $5.4 billion
Amgen to invest $900m in Ohio manufacturing facility
Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.
AbbVie Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis
AbbVie recently secured FDA approval for RINVOQ (Upadacitinib) to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company&...
Portage Biotech Reports Confirmatory Preclinical Results
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
EC grants orphan drug designation to Dyne Therapeutics’ Duchenne muscular dystrophy
The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks
Gilead Sciences’ stock is up 12% this year, topping a 1% gain for the NYSE Arca Pharmaceutical Index. Chief Executives don’t usually brag about paying high tax rates.
Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis
Ipsen’s elafibranor (sold under the brand name Iqirvo) has shown promise as a treatment for primary sclerosing cholangitis (PSC),
Eli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical Histrory
Eli Lilly's New Weight Loss Drug May Have the Worst Name in Pharmaceutical Histrory
Earlier Ocrevus treatment may reduce cerebellar shrinkage in MS
Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination
Thermo Fisher Scientific to invest $2bn
Thermo Fisher Scientific to invest $2bn into US manufacturing capabilities
Scribe Therapeutics to Unveil Latest Preclinical Data
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
72
73
74
75
76
77
78
79
80